Roche Says Phase III Celestimo Study Hits Primary Endpoint
Roche said its Phase III Celestimo study met the primary endpoint in follicular lymphoma.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.